Literature DB >> 1559125

Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum.

R A Lawrence1, R L Jones, N H Wilson.   

Abstract

1. A study of the effects of prostaglandin E2 (PGE2) and eleven synthetic analogues on the guinea-pig isolated ileum preparation has revealed three distinct contractile actions, each associated with a different prostaglandin E (EP-) receptor subtype. In addition, PGI2 (prostacyclin) and its stable analogues can activate prostaglandin I (IP-) receptors to elicit both contraction and relaxation of the ileum. 2. Two of the PGE actions involve direct stimulation of the smooth muscle, being unaffected by 1 microM morphine treatment. One action is blocked by AH 6809 at micromolar concentrations and ICI 80205 and 16,16-dimethyl PGE2 are particularly potent agonists. Activation of EP1-receptors appears to be involved. The second action is unaffected by AH 6809; sulprostone and MB 28767 are potent agonists. Comparison with agonist potency rankings on the guinea-pig vas deferens indicates that EP3-receptors may be involved. 3. The third PGE effect and the stimulant PGI effect are blocked by morphine, indicating enteric neurones and/or sensory nerve terminals as sites of action. EP2-receptors may be involved in the PGE action, in view of the marked effect of morphine on the contractile actions of misoprostol, 11-deoxy PGE2-1-alcohol, 11-deoxy PGE1 and butaprost, all of which show some selectivity for EP2-receptors. The PGI action is most easily studied with cicaprost (EC25 = 1.3 nM), since iloprost, carbacyclin and to a lesser extent PGI2 also have agonist activity at EP1-receptors. 4. The contractile action of 17-phenyl-omega-trinor PGE2 on the ileum is unaffected by morphine. Since this analogue shows only weak agonist activity on the rabbit jugular vein (EP2 preparation) and guinea-pig vas deferens (EP3), it may be a more useful standard agonist than PGE2 in EPl1-receptor studies.5. In the presence of morphine and AH 6809, cicaprost inhibits histamine-induced contractions (IC25 = 22 nM). PGI2 and iloprost show mixed inhibitory/potentiating actions, whereas carbacyclin only potentiates histamine contractions. This IP-receptor-mediated inhibition may account for the bell-shaped log concentration-response curve of cicaprost (no inhibitors present) and the very marked block of iloprostinduced contractions by AH 6809.6. We have found no evidence for either IP-receptors mediating direct contraction or EP-receptors mediating inhibition of the ileum longitudinal smooth muscle, as has been suggested in the literature.7. In view of the complexity of prostanoid action on the guinea-pig ileum we feel that the preparation must be used with caution to ascertain the EPl agonist or antagonist potencies of novel compounds.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1559125      PMCID: PMC1908640          DOI: 10.1111/j.1476-5381.1992.tb14245.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Antinociception and physical dependence produced by [D-Arg2] dermorphin tetrapeptide analogues and morphine in rats.

Authors:  K Chaki; S Kawamura; K Kisara; S Sakurada; T Sakurada; Y Sasaki; T Sato; K Susuki
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

2.  Relaxant potencies of prostaglandin E analogues on rabbit jugular vein.

Authors:  R A Lawrence; R L Jones; N H Wilson
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

3.  AH6809, a prostaglandin DP-receptor blocking drug on human platelets.

Authors:  R J Keery; P Lumley
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

Review 4.  Biological activities of pure prostaglandins.

Authors:  E W Horton
Journal:  Experientia       Date:  1965-03-15

5.  10,10-Difluoro-13-dehydroprostacyclin: a chemically and metabolically stabilized potent prostacyclin.

Authors:  J Fried; D K Mitra; M Nagarajan; M M Mehrotra
Journal:  J Med Chem       Date:  1980-03       Impact factor: 7.446

6.  Target sites for the inhibition of prostacyclin effect in guinea-pig ileum.

Authors:  R M Gaion; L Gambarotto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-10       Impact factor: 3.000

7.  The action of prostanoid receptor agonists and antagonists on smooth muscle and platelets.

Authors:  R M Eglen; R L Whiting
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

8.  The role of adrenergic, purinergic and opiate receptors in the control of prostacyclin-induced contraction in the guinea-pig ileum.

Authors:  R M Gaion; M Trento
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-09

9.  Studies on the characterisation of prostanoid receptors: a proposed classification.

Authors:  I Kennedy; R A Coleman; P P Humphrey; G P Levy; P Lumley
Journal:  Prostaglandins       Date:  1982-11

10.  Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.

Authors:  P M Tymkewycz; R L Jones; N H Wilson; C G Marr
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

View more
  38 in total

1.  Pharmacological characterization of prostanoid receptors mediating vasoconstriction in human umbilical vein.

Authors:  Federico Manuel Daray; Ana Itatí Minvielle; Soledad Puppo; Rodolfo Pedro Rothlin
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

2.  Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations.

Authors:  R L Jones; D F Woodward; J W Wang; R L Clark
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys.

Authors:  B'Ann True Gabelt; Elizabeth A Hennes; Mark A Bendel; Chase E Constant; Mehmet Okka; Paul L Kaufman
Journal:  J Ocul Pharmacol Ther       Date:  2009-02       Impact factor: 2.671

4.  Ontogenic increase in PGE2 and PGF2 alpha receptor density in brain microvessels of pigs.

Authors:  D Y Li; D R Varma; S Chemtob
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

5.  The EP1/EP3 receptor agonist 17-pt-PGE2 acts as an EP4 receptor agonist on endothelial barrier function and in a model of LPS-induced pulmonary inflammation.

Authors:  Anna Theiler; Viktoria Konya; Lisa Pasterk; Jovana Maric; Thomas Bärnthaler; Ilse Lanz; Wolfgang Platzer; Rufina Schuligoi; Akos Heinemann
Journal:  Vascul Pharmacol       Date:  2016-09-21       Impact factor: 5.773

6.  Inhibition of rat colon contractility by prostacyclin (IP-) receptor agonists: involvement of NANC neurotransmission.

Authors:  Y M Qian; R L Jones
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

7.  Prostaglandin E2 acts via multiple receptors to regulate plasminogen-dependent proteolysis in the primate periovulatory follicle.

Authors:  Nune Markosyan; Diane M Duffy
Journal:  Endocrinology       Date:  2008-09-25       Impact factor: 4.736

8.  Inhibition of vagally mediated gastric acid secretion by activation of central prostanoid EP3 receptors in urethane-anaesthetized rats.

Authors:  K Yokotani; Y Okuma; Y Osumi
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

9.  Characterization of the PGE2 receptor subtype in bovine chondrocytes in culture.

Authors:  A J de Brum-Fernandes; S Morisset; G Bkaily; C Patry
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 10.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.